Update on pain management: new methods of opiate delivery.
A review of the literature revealed a real need for pain management methods that are easy for patients to use, give continuous and/or rapid pain relief, and have minimal side effects. Cole (2003) noted that health care providers who stay informed about opioid therapy for pain management are performing one of the basic steps for providing good patient care. Multiple headlines in recent years identified the dangers of opiate abuse and deaths from overdoses. Nurses are the front-line providers in patient education and safety for all forms of medication. Taking a careful history and providing adequate patient education can help to prevent many problems with medications, including opiates for pain management.
New medications and delivery systems are available to help patients manage their pain. In this article, some of the more innovative opiate delivery systems that enhance pain management are reviewed. With any medication and delivery system, a careful history can direct the patient to the most appropriate pain management method. The nurse should take a detailed drug history, including allergies, adverse effects, and side effects of past medications. Asking which medication worked or did not perform well in the past is important, as is asking a patient how he or she takes a medication. A patient may have a fear of becoming addicted to the medication. The nurse should know that only a small percentage of patients actually do become addicted (Field, 2007); explaining this to the patient can help engage him or her as a partner in a personal pain management plan. Field (2007) also noted that this fear of addiction may result in undertreatment of a patient with genuine pain.
One of the newest opioid forms to become available is the fentanyl buccal tablet (Fentora[R]), which was developed to manage breakthrough pain. The buccal tablet is an effervescent formulation which is a fast, effective route of medication administration for breakthrough pain (Webster, 2006). Two separate studies done at Beth Israel Medical Center in New York (Portenov, Messina, Xie, & Peppin, 2007; Portenov, Taylor, Messina, & Tremmel, 2006) evaluated use of fentanyl buccal tablets for cancer-related pain and for opioid-treated patients with chronic low back pain. Both studies demonstrated that the fentanyl buccal tablets were effective and well tolerated in these groups of patients. Rapinyl[TM] is another fentanyl sublingual tablet still in trials (D'Arcy, 2007).
The fentanyl in these tablets is absorbed through the buccal mucosa, aided by an effervescent reaction that produces large shifts in pH (Webster, 2006). The buccal tablets take about 10-15 minutes to dissolve between the gums and upper molar; they have greater bioavailability due to the fact that they bypass the gastrointestinal tract and first-pass liver metabolism. They may be effective not only for breakthrough or sudden pain but also for anticipated pain, such as that experienced by an orthopedic surgical patient scheduled to attend a rehabilitation session. Side effects are similar to other opioids, including nausea, dizziness, and headache; no reports of respiratory depression were noted in the literature. Prior to administering the buccal tablet, the nurse should examine the patient for any oral lesions, dental abscesses, or difficulties with salivation.
A slightly older form of fentanyl is the more familiar fentanyl lozenge or lollipop (Actiq[R]). The lozenge was developed for patients with breakthrough cancer pain or those who were already taking opiates for persistent pain (Cephalon, Inc., 2006). It also was studied previously for postoperative pain (Ashburn et al., 1993; Lichtor et al., 1999) but currently is indicated only for breakthrough pain related to cancer in patients already taking other opioids (Cephalon, Inc., 2006). Hanks, Nugent, Higgs, and Busch (2004) found oral lozenges to be effective in a variety of patients, with no patient reporting dissatisfaction with the drug or delivery system. Their research indicated that this delivery system offered a unique, fast-acting pain management strategy that most patients found easy to use.
The convenience of this delivery system also makes it one of the most difficult to maintain in a household, particularly one with small children or pets. It is offered as a hard, sugar-sweetened lozenge on a small stick. The patient places it in the mouth and actively sucks on the medication, rotating the stick between the cheeks and gums. The drug's manufacturer issued special warnings for disposing of unused medication and storage of the medication system. The stick must be cleaned under hot water and then placed in the trash. Unfinished lozenges should be stored in a special container out of the reach of others (Cephalon, Inc., 2006). Patient teaching includes use of the medication, safe storage of unused and partially used lozenges, and disposal of the used sticks. Side effects are similar to other opioid analgesics, including orthostatic hypotension, bradycardia, respiratory depression, and risk of dependency (Turkoski, Lance, & Bonfiglio, 2006).
Fentanyl also is available in a transdermal patch, which has been marketed longer than the unique oral forms of the drug. The patch is applied to clean, dry, hairless skin. It then slowly releases medication over a 72-hour period to manage chronic moderate-to-severe pain (U.S. National Library of Medicine, 2006). A review of the literature revealed multiple problems with overdose and abuse since the patch became available. Overdose can occur if the patient uses more than the prescribed dose, if body temperature reaches 40[degrees]C, or the patient's skin is exposed to a direct heat sources (Turkoski et al., 2006). Abuses documented in the literature include patients extracting medication from the patch then injecting or swallowing it, applying multiple patches, or mixing the extracted medication with heroin (Boddiger, 2006; Brown University, 2005). The Food and Drug Administration issued a Public Health Advisory in 2005 warning practitioners to use safety information sheets and teach patient precautions, including signs and symptoms of overdose, techniques for applying the patches, and use of other medications while using the patches ("New Drugs/Drug News," 2005). Cole (2003) noted that while controlled-release medications have positive effects for patients, such as improved sleep, ability to participate in rehabilitation, and enhanced pain management, their longer half-life leads to more toxicity in overdoses.
IONSYS[R] is another type of transdermal system for fentanyl delivery (Ortho-McNeil, Inc., 2006). A credit card-sized patch with a small battery, it uses a low-intensity electrical field to transport the medication through the skin. The patient activates the device to deliver a dose of medication; the delivery system also turns off when it is out of medication. IONSYS is being used currently in postoperative patients to offer freedom from carrying or moving around with a bulky pump system. The side effect profile is similar to other opioids, but dosing can be set before the device is placed on the patient (D'Arcy, 2007). IONSYS is approved only for use in hospitalized patients and must be removed before the patient is discharged.
Buprenorphine also is being studied in a transdermal delivery system for treating severe cancer pain and chronic non-cancer pain. The system is still in trials in the United States (Evans & Easthope, 2003; Sorge & Sitti, 2004), but is available in the United Kingdom under the brand name BuTrans[R].
Intrathecal infusion (implantable pumps) of morphine has been used previously for pain treatment. Studies are now underway to evaluate the effectiveness of both fentanyl and sufentanil (an analog of fentanyl) in intrathecal delivery systems. Currently both of these drugs are approved for short-term epidural administration, such as during and after childbirth or surgery. Studies about more long-term use of these drugs in intrathecal infusions are underway to evaluate their stability and effectiveness (Waara-Wolleat, Hildebrand, & Stewart, 2006).
DepoDur[R] is the brand name for a single dose, extended-release epidural morphine liposome injection. Recent studies have evaluated its effectiveness for post-Caesarean analgesia as well as pain management after lower abdominal surgery when compared to conventional epidural morphine (Carvalho, Roland, Chu, Campitelli, & Riley, 2007; Gambling, Hughes, Martin, Horton, & Manvelian, 2005). Findings indicated the delivery was effective with no serious adverse effects, and subjects required less breakthrough analgesia compared to other patients who used conventional epidural morphine.
More people are living with chronic pain. Whether the pain is malignant or non-malignant, the nurse can assist the patient in correct use of the various forms of opioid medications; teach the importance of home safety, especially related to storage and delivery; and educate the patient about addiction potential and adverse effects, especially those that may be life-threatening. Current education about new medications, delivery systems, and possible abuses helps the nurse be a better partner in the patient's pain management plan.
Ashbum, M.A., Lind, G.H., Gillie, M.H., de Boer, A.J., Pace, N.L, & Stanley, T.H. (1993). Oral transmucosal fentanyl citrate (OTFC) for the treatment of postoperative pain. Anesthesia & Analogue, 76(2), 377-381.
Boddiger, D. (2006). Fentanyl laced street drugs "kill hundreds." The Lancet, 366(9535), 569-570.
Brown University. (2005, October). Fentanyl patch abuse leads to overdose deaths. The Brown University Child & Adolescent Psychopharmacology Update, 7(10), 6.
Carvalho, B., Roland, LM., Chu, L.F., Campitelli, V.A., & Riley, E.T. (2007). Single-dose, extended-release epidural morphine (DepoDur) compared to conventional epidural morphine for postcesarean pain. Anesthesia & Analogue, 105(1), 176-183.
Cephalon, Inc. (2006). Actiq. Retrieved June 24, 2007, from http://www.actiq.com/ physicians/aboutbtcp/default.asp
Cole, B.E. (2003). Balancing pain management and professional risks. Practical Pain Management, 3(2), 23-27.
D'Arcy, Y. (2007). Going the distance: New pain treatments provider longer, stronger relief. Advance for Nurse Practitioners, 15(6), 32-36.
Evans, H.C., & Easthope, S.E., (2003). Transdermal buprenorphine. Drugs, 63(19), 1999-2010.
Field, R.I. (2007). Health care and law: America's drug abuse problem increasingly starts in the medicine cabinet. P&T, 32(6), 331-332.
Gambling, D., Hughes, T., Martin, G., Horton, W., & Manvelian, G. (2005). A comparison of DepoDur, a novel single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery. Anesthesia & Analogue, 100(4), 1065-1074.
Hanks, G.W., Nugent, M., Higgs, C.M.B., & Busch, M.A. (2004). Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: An open, multi-centre, dose-titration and long-term use study. Palliative Medicine, 18(8), 698-704.
Joint Commission on Accreditation of Healthcare Organizations. (2000). Pain assessment and management, an organizational approach. Oakbrook Terrace, IL: Author.
Lichtor, J.L., Sevarino, F.B., Joshi, G.P., Busch, M.A., Nordbrock, E., & Ginsburg, B. (1999). The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesthesia& Analogue, 89(4), 723-727.
New drugs/Drug news: Fentanyl patch advisory. (2005). P&T, 30(8), 437.
Ortho-McNeil, Inc. (2006). IONSYS system. Retrieved July 1, 2007, from http:// www.ionsys.net/
Portenov, R.K., Messina, J., Xie, F., & Peppin, J. (2007). Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: A randomized, placebo-controlled study. Current Medical Research Opinion, 23(1), 223-233.
Portenov, R.K., Taylor, D., Messina, J., & Tremmel, L. (2006). A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clinical Journal of Pain, 22(9), 805-811.
Sorge, J., & Sitti, R. (2004). Transdermal buprenorphine in the treatment of chronic pain: Results of a phase III, multi-center, randomized, double-blind, placebo-controlled study. Clinical Therapeutics, 26(11), 1808-1820.
Sternberg, S. (2005, May 8). Chronic pain: The enemy within. USA Today, p. A1.
Turkoski, B.B., Lance, B.R., & Bonfiglio, M.F. (2006). Drug information handbook for advanced practice nursing. Hudson, OH: Lexi-Comp.
U.S. National Library of Medicine. (2006). Fentanyl skin patches. Retrieved June 18, 2007, from http://www.nlm.nih.gov/ medlineplus/druginfo/medmaster/a60 1202.html
Waara-Wolleat, K.L., Hildebrand, K.R., & Stewart, G.R. (2006). A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. Pain Medicine, 7(3), 251-259.
Wallis, C. (2005, February 28). The right and wrong way to treat pain. Time, 165(9), 46-57.
Webster, LR. (2006). Fentanyl buccal tablets. Expert Opinion on Investigational Drugs, 15(11), 1469-1473.
Lisa Cranwell-Bruce, MS, RN, FNP-C, is a Clinical Instructor, Byridine F. Lewis School of Nursing, College of Health and Human Sciences, Georgia State University, Atlanta, GA.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Nursing Pharmacology|
|Date:||Oct 1, 2007|
|Previous Article:||The medical-surgical nurse's guide to ovarian cancer: Part II.|
|Next Article:||Immunizations for older adults.|